» Articles » PMID: 35332158

Gastrointestinal Involvement in Parkinson's Disease: Pathophysiology, Diagnosis, and Management

Overview
Date 2022 Mar 25
PMID 35332158
Authors
Affiliations
Soon will be listed here.
Abstract

Growing evidence suggests an increasing significance for the extent of gastrointestinal tract (GIT) dysfunction in Parkinson's disease (PD). Most patients suffer from GIT symptoms, including dysphagia, sialorrhea, bloating, nausea, vomiting, gastroparesis, and constipation during the disease course. The underlying pathomechanisms of this α-synucleinopathy play an important role in disease development and progression, i.e., early accumulation of Lewy pathology in the enteric and central nervous systems is implicated in pharyngeal discoordination, esophageal and gastric motility/peristalsis impairment, chronic pain, altered intestinal permeability and autonomic dysfunction of the colon, with subsequent constipation. Severe complications, including malnutrition, dehydration, insufficient drug effects, aspiration pneumonia, intestinal obstruction, and megacolon, frequently result in hospitalization. Sophisticated diagnostic tools are now available that permit more detailed examination of specific GIT impairment patterns. Furthermore, novel treatment approaches have been evaluated, although high-level evidence trials are often missing. Finally, the burgeoning literature devoted to the GIT microbiome reveals its importance for neurologists. We review current knowledge about GIT pathoanatomy, pathophysiology, diagnosis, and treatment in PD and provide recommendations for management in daily practice.

Citing Articles

Use and misuse of domperidone in patients living with Parkinson disease in France.

Januel E, Corvol J, Remy P, Meissner W, Thiriez C, Lanore A Fundam Clin Pharmacol. 2025; 39(2):e70002.

PMID: 40062736 PMC: 11892330. DOI: 10.1111/fcp.70002.


Epigenetic Biomarkers Driven by Environmental Toxins Associated with Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis in the United States: A Systematic Review.

Newell M, Aravindan A, Babbrah A, Halden R Toxics. 2025; 13(2).

PMID: 39997929 PMC: 11860158. DOI: 10.3390/toxics13020114.


Lewy body diseases and the gut.

Sampson T, Tansey M, West A, Liddle R Mol Neurodegener. 2025; 20(1):14.

PMID: 39885558 PMC: 11783828. DOI: 10.1186/s13024-025-00804-5.


Optical detection of the spatial structural alteration in the human brain tissues/cells and DNA/chromatin due to Parkinson's disease.

Alharthi F, Solanki D, Apachigawo I, Xiao J, Khan M, Pradhan P ArXiv. 2025; .

PMID: 39764409 PMC: 11703318.


Diagnosis and treatment of autonomic failure, pain and sleep disturbances in Parkinson's disease: guideline "Parkinson's disease" of the German Society of Neurology.

Fanciulli A, Sixel-Doring F, Buhmann C, Krismer F, Hermann W, Winkler C J Neurol. 2025; 272(1):90.

PMID: 39751950 PMC: 11698777. DOI: 10.1007/s00415-024-12730-5.


References
1.
Eadie M, Tyrer J . ALIMENTARY DISORDER IN PARKINSONISM. Australas Ann Med. 1965; 14:13-22. DOI: 10.1111/imj.1965.14.1.13. View

2.
Eadie M, Tyrer J . RADIOLOGICAL ABNORMALITIES OF THE UPPER PART OF THE ALIMENTARY TRACT IN PARKINSONISM. Australas Ann Med. 1965; 14:23-7. DOI: 10.1111/imj.1965.14.1.23. View

3.
Coelho M, Marti M, Tolosa E, Ferreira J, Valldeoriola F, Rosa M . Late-stage Parkinson's disease: the Barcelona and Lisbon cohort. J Neurol. 2010; 257(9):1524-32. DOI: 10.1007/s00415-010-5566-8. View

4.
Jost W . Gastrointestinal dysfunction in Parkinson's Disease. J Neurol Sci. 2009; 289(1-2):69-73. DOI: 10.1016/j.jns.2009.08.020. View

5.
Fasano A, Visanji N, Liu L, Lang A, Pfeiffer R . Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol. 2015; 14(6):625-39. DOI: 10.1016/S1474-4422(15)00007-1. View